Core Insights - Immutep's proprietary soluble LAG-3 protein, efti, is being developed as a cancer treatment in combination with Merck's Keytruda, showing promising results in clinical trials for head and neck squamous cell carcinoma (HNSCC) [1][10]. Efficacy and Safety - The combination therapy of efti and Keytruda achieved an objective response rate (ORR) of 35.5% and a disease control rate (DCR) of 58.1% in patients with negative PD-L1 expression, significantly higher than historical controls [2][11]. - The treatment demonstrated a complete response rate of 9.7%, compared to 0% in historical controls for anti-PD-1 monotherapy [2]. - More than 50% of patients treated with the combination therapy have maintained their response for at least six months, with no new safety concerns reported [3]. Regulatory and Development Plans - Based on the positive efficacy and safety data, the company plans to engage with regulatory agencies regarding the next steps for efti [4]. - In addition to HNSCC, Immutep is exploring efti in combination with other agents for various solid tumors, including non-small cell lung cancer and metastatic breast cancer [5]. Market Position and Competitors - Merck's Keytruda continues to expand into new indications and markets, reinforcing its position in the oncology market, accounting for 47% of Merck's pharmaceutical sales in 2023 [6][14]. - Immutep currently holds a Zacks Rank 3 (Hold), while other companies in the biotech sector, such as Arcutis Biotherapeutics and Annovis Bio, have better rankings [7][15]. Stock Performance - Year to date, shares of Immutep have decreased by 3.7%, contrasting with a 2.5% decline in the industry [18].

Results Durability of Responses and Favourable Safety regulatory agencies. Efti has received FDA Fast Track designation in 1L HNSCC regardless of PD-L1 expression. The prevalence for CPS <1, CPS 1-19, and CPS >20 PD-L1 expression levels are approximately 20%, 30%, and 50% of the HNSCC patient population, respectively.3 KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. About Eftilagimod Alfa (Efti) Immutep is a clinical-stage biotechnology com ...

Guide to Identifying Oversold Stocks This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering IMMP in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 6.7% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term. Moreover, IMMP currently has a ...

SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces a License Agreement with Cardiff University granting the Company exclusive rights to develop and commercialise anti-LAG-3 small molecules. Professor Andrew Godkin of Cardiff University said: "Our collaboration with Immutep has been exciting and fruitful, res ...

Media Release SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces a License Agreement with Cardiff University granting the Company exclusive rights to develop and commercialise anti-LAG-3 small molecules. A number of promising compounds that block LAG-3, an immune checkpoint known to reduce the immune system' ...

The Institutional Offer raised gross proceeds of approximately A$89.6 million at an offer price of A$0.38 per New Share, consisting of approximately A$72.0 million under the Placement and approximately A$17.6 million under the Institutional Entitlement Offer. Dr Russell Howard, Chairman of Immutep, said: "Immutep has gone from strength to strength with the team working tirelessly to deliver our late-stage clinical program in three cancer areas: lung, breast, and head and neck cancer. As we traverse our path ...

Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) (Immutep or the Company) is pleased to announce the successful completion of its institutional placement (Placement) and the institutional component (Institutional Entitlement Offer) of its 1 for 16 pro rata accelerated non-renounceable entitlement offer (Entitlement Offer and, together with the Placement, the Offer) of new fully paid ordinary shares in Immutep (New Shares). The Placement and Instit ...

Core Viewpoint - Immutep Limited has entered a collaboration with MSD to conduct a Phase III trial (TACTI-004) evaluating the efficacy of efti in combination with KEYTRUDA and standard chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) [1][4][5] Group 1: Trial Details - TACTI-004 will enroll approximately 750 patients, regardless of PD-L1 expression, to address the entire NSCLC market eligible for anti-PD-1 therapy [1][3] - The trial is designed as a 1:1 randomized, double-blind, multinational, controlled study with dual primary endpoints of progression-free survival and overall survival [3][4] - The collaboration allows both companies to seek marketing authorization for the combination treatment while retaining commercial rights to their respective compounds [5] Group 2: Efficacy and Safety - Efti, in combination with KEYTRUDA and chemotherapy, has shown compelling efficacy and favorable safety across all levels of PD-L1 expression in prior trials [1][2][6] - Over 75% of patients in previous trials had a PD-L1 Tumor Proportion Score (TPS) of less than 50%, demonstrating strong efficacy in typically less responsive patients [7] - The combination therapy has been well tolerated, indicating a promising safety profile [7] Group 3: Background and Significance - Lung cancer is the second most common cancer, with NSCLC accounting for approximately 80-85% of all lung cancers, impacting an estimated 1.87 million people annually [9] - The collaboration aims to set a new standard of care by improving clinical outcomes and broadening the patient response across the NSCLC population [2][4] - Efti is a first-in-class antigen presenting cell activator that stimulates both innate and adaptive immunity, enhancing the immune response against cancer [10][11]

Media Release Complete Response Patient Case Study The patient with a confirmed complete response (CR) was diagnosed with triple-negative breast carcinoma (TNBC) in 2019 and has failed multiple lines of therapy including a CDK 4/6 inhibitor for ER+/PR+ metastasis. During the immuno-oncology (IO)-chemotherapy treatment of efti and paclitaxel, this patient achieved a partial response (PR) that subsequently turned into a CR. This patient's ongoing CR has been maintained since stopping paclitaxel and being trea ...

Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trialFour of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are rarely observed with standard therapiesSoft tissue sarcoma is a hard-to-treat orphan disease with poor prognosis & high unmet medical needAdditional data from EFTISARC-NEO planned for a medical conference in H2 ...